All announcements

Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

Announcement Date

Pfizer and Biontech Conclude Phase 3 Study of Vaccine Candidate, Meeting All Primary Efficacy Endpoints

November 18, 2020

Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

November 9, 2020

Norpace CR Drug Shortage Communication – Supply Status

October 19, 2020

U.S. FDA Approves Xeljanz (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)

September 30, 2020

Approval from German authority to start clinical trial of COVID-19 vaccine

April 23, 2020

COVID-19 Information Update for U.S. Health Care Professionals

April 15, 2020

U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy.

On April 8th, 2020, Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy. The approval is based on results from the BEACON CRC trial, the only Phase 3 trial to specifically study patients with previously treated metastatic CRC with a BRAFV600E mutation.
April 8, 2020

Pfizer Advances Battle Against COVID-19 on Multiple Fronts

April 1, 2020


First participants dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine. Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021
April 1, 2020

Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development

April 1, 2020

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

April 1, 2020